The Renal Safety of Tenofovir Alafenamide in HBV-related Acute-on-chronic Liver Failure: Real-World Study
Status:
Completed
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
Tenofovir alafenamide (TAF) and entecavir (ETV) are the preferred agents in patients with
predisposing factors for nephrotoxicity, but few studies to date have directly compared the
renal safety of the two antiviral drugs in patients with acute-on-chronic liver failure
(ACLF). Hence, the investigators compared the risk of kidney function decline among patients
with HBV related acute-on-chronic liver failure (HBV-ACLF) treated with ETV or TAF.From April
2020 to June 2021, a total of 272 HBV-related ACLF hospitalized patients in the Xiangya
Hospital of Central South University were enrolled in this prospective study. Chronic
hepatitis B was diagnosed by hepatitis B surface antigen and/or hepatitis B virus
deoxyribonucleic acid (HBV-DNA) positivity for ≥6 months. ACLF was diagnosed based on the
criteria proposed by the APASL Working Party. All patients received antiviral therapy with
TAF (25 mg QD, n=100) or ETV (0.5mg QD, n=172), and comprehensive medical treatments.
Clinical and laboratory data were collected to evaluate the progression of chronic kidney
disease (CKD) .